In this study, we have identified three surface markers in BCC—LYPD3, TACSTD2, and LY6D—that reliably define the nMRTF BCC cell state and can be used as prognostic markers for resistance to SMOi and responsiveness to AP-1 inhibitors. This evidence concerns the gene JUN and skin basal cell carcinoma.